"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Oncology - The Woodlands, Gynecologic Oncology conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 3 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology - The Woodlands, Gynecologic Oncology" #1 sponsor was "ImmunoGen, Inc." with 3 trials, followed by "Clovis Oncology, Inc." with 1 trials sponsored, "I-Mab Biopharma US Limited" with 1 trials sponsored, "NuCana plc" with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology - The Woodlands, Gynecologic Oncology" #1 collaborator was "Gynecologic Oncology Group" with 3 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Foundation Medicine" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology - The Woodlands, Gynecologic Oncology" are "Epithelial Ovarian Cancer" (4 trials), "Fallopian Tube Cancer" (4 trials), "Ovarian Cancer" (4 trials), "Peritoneal Cancer" (2 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "Texas Oncology - The Woodlands, Gynecologic Oncology" in a lesser frequency.

Most popular intervention types in "Texas Oncology - The Woodlands, Gynecologic Oncology" are "Drug" (8 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Mirvetuximab Soravtansine" (2 trials), "Paclitaxel" (2 trials), "Pegylated liposomal doxorubicin" (2 trials), "Topotecan" (2 trials) and "Elacestrant" (1 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology - The Woodlands, Gynecologic Oncology" are 6 trials for "Female" genders and 2 trials for "All" genders.

Currently, there are NaN active trials in "Texas Oncology - The Woodlands, Gynecologic Oncology". undefined are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Texas Oncology - The Woodlands, Gynecologic Oncology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology - The Woodlands, Gynecologic Oncology, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".